8-K: Biotricity Reports Record Margins, Revenues, and Cashflows with 21.7% Sales Growth in Q3 Fiscal Year 2025

Biotricity announces strong Q3 fiscal year 2025 results, featuring record margins, revenues, and cash flows, driven by a 21.7% year-over-year sales increase.

Summary

• Biotricity reported a 21.7% year-over-year revenue increase in Q3 fiscal year 2025, reaching $3.6 million.
• The company achieved record gross margins of 76.4%, up from 72.9% in the same period last year.
• Biotricity experienced a 56.7% decrease in net loss, reducing it to $1.32 million.
• Recurring technology fees comprised 94% of total revenue, with an 81.4% gross profit percentage.
• The company achieved positive cash flow on a current operating basis for the second consecutive quarter, up 114.5% from the prior quarter.
• SG&A expenses were reduced by 20.5% to $2.38 million.
• The company's recurring technology fees rose 21.8% year-over-year to $3.39 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, including revenue growth, improved margins, and reduced net loss. The achievement of positive cash flow and focus on cost control further contribute to the positive sentiment.

Positives

• Revenue increased by 21.7% year-over-year, indicating strong sales performance.
• Gross margins improved significantly, reflecting enhanced profitability.
• Net loss decreased substantially, demonstrating improved financial health.
• Positive cash flow from operations was achieved for the second consecutive quarter, showcasing financial stability.
• Recurring technology fees constitute a significant portion of revenue, providing a stable income stream.
• SG&A expenses were reduced, indicating effective cost management.
• The company is expanding its customer base, particularly within hospital networks.

Negatives

• The company still reported a net loss of $1.32 million, despite significant improvements.
• The company is not yet profitable overall.

Risks

• The company's future performance is subject to various risks and uncertainties, including the ability to obtain additional financing and the impact of government regulations.
• The company's success depends on the continued development and commercialization of its products.
• The company faces competition from other players in the remote health monitoring market.

Future Outlook

Management expects to continue to see cash flows improve and anticipates continued strong performance in overall blended gross margins.

Management Comments

• Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, stated that the company continued its mission to innovate and develop transformative healthcare technologies, while demonstrating a strong commitment to automation, operating efficiency, and financial discipline.
• Management is pleased to see revenue and margins trending upwards.
• The company is focused on achieving sustained positive cash flow by accelerating revenue growth while maintaining cost discipline.

Industry Context

Biotricity operates in the growing remote health monitoring market, leveraging technology-as-a-service (TaaS) to provide diagnostic and post-diagnostic solutions for chronic conditions. The company's focus on AI-driven solutions aligns with the industry trend of using artificial intelligence to improve healthcare outcomes.

Comparison to Industry Standards

• Given Biotricity's focus on remote cardiac monitoring, comparable companies include iRhythm Technologies, which offers the Zio XT service for long-term continuous monitoring, and BioTelemetry, now part of Philips, which provides remote cardiac monitoring services.
• Biotricity's gross margin of 76.4% is competitive within the medical device and remote monitoring industry; iRhythm Technologies, for example, has reported gross margins in a similar range.
• The growth in recurring technology fees is a positive indicator, as it aligns with the industry's shift towards subscription-based revenue models, similar to companies like Teladoc Health in the telehealth space.

Stakeholder Impact

• Shareholders will likely view the strong financial results positively.
• Employees may benefit from the company's improved financial performance and growth prospects.
• Customers will continue to receive remote monitoring and diagnostic solutions.
• The company's success could lead to increased demand for its suppliers' products and services.
• Creditors may view the company as a lower-risk borrower due to its improved financial stability.

Next Steps

• Management will file full details of the company's financial results with the SEC on Form 10-Q.
• Investors can access a replay of the financial results call via the Investors section of the Biotricity website.

Key Dates